Shares of cancer treatment company ArQule surge 100 percent on Merck acquisition
By Morgan Drug giant Merck & Co. agreed Monday to acquire ArQule, a cancer-treating biopharmaceutical company, for $20 per share in cash for a total equity value of around $2.7 …
Read More